Michael Schmertzler | Chairman
Mr. Schmertzler has served as a member of PTC's board of directors since August 2001 and as the Chairman of the board of directors since November 2004. Mr. Schmertzler has taught private equity at Yale University in the Department of Economics and graduate schools since 1998. He is also currently the independent director of Lehman Commercial Paper, Inc., the largest subsidiary of the liquidating post-bankruptcy Lehman Brothers estate. He has been a senior manager of institutional private equity capital since 1986, previously serving as Co-Head of Credit Suisse First Boston Equity Partners and President of the Morgan Stanley Leveraged Capital Funds. Mr. Schmertzler has also been a Managing Director in the Mergers and Acquisitions Department of Morgan Stanley and head of that firm’s biotechnology and global insurance industry groups; and head of international investment banking and capital markets of Shearson Lehman Brothers. Prior to its acquisition in 1984 by American Express, Mr. Schmertzler was the Chief Financial Officer of Lehman Brothers. From 2008-2012, Mr. Schmertzler was the founding CEO of Kolltan Pharmaceuticals, a Yale sponsored biotechnology spin off. Mr. Schmertzler has served as a director or senior private investor at Cain Chemical, Colt Industries, Cytokinetics, Idenix, Segway and other industrial and early stage biotechnology and technology companies. He currently serves on the boards of the Addison Gallery of American Art and the Manhattan Theater Company and has previously served on the boards of Phillips Academy Andover, the Credit Suisse First Boston Foundation, the National Outdoor Leadership School, and the New York Academy of Sciences. Mr. Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History and City Planning and an M.B.A. from the Harvard Business School.
Allan Jacobson, Ph.D. | University of Massachusetts Medical School
Allan Jacobson, Ph.D. is a co-founder of PTC and is the Gerald L. and Zelda S. Haidak Distinguished Professor of Cell Biology at the University of Massachusetts Medical School. He has served as a member of the PTC board of directors since the company's inception in 1998, previously served as Chairman of the board of directors from 1998 to 2004, and, since 2000, has served as Chairman of the scientific advisory board. In 1982, Dr. Jacobson co-founded Applied bioTechnology, Inc., a biotechnology company, and served as its chairman until its sale in 1991. From 1987 to 1990, Dr. Jacobson served as special limited partner at Euclid Partners, a venture capital firm. Dr. Jacobson has been the Chairman of the Department of Microbiology and Physiological Systems at the UMass Medical School since 1994, and in 2014, was awarded the Medical School’s Chancellor’s Medal for Distinguished Scholarship. Dr. Jacobson received a Ph.D. from Brandeis University in 1971, has authored over 100 publications in the field of post-transcriptional control processes, and is an elected member of the American Academy of Microbiology.
Adam Koppel, M.D., Ph.D | Bain Capital
Adam Koppel, M.D., Ph.D. has served as a member of PTC's board of directors since March 2013. Dr. Koppel is Managing Director at Bain Capital. Previously, he was Executive Vice President, Corporate Development & Strategy of Biogen, where he was responsible for leading corporate strategy and portfolio management. Prior to Biogen, Dr. Koppel was a Managing Director of Brookside Capital, the public equity affiliate of Bain Capital. He has also served as Associate Principal with McKinsey & Company where he consulted to companies in the pharmaceutical and biotechnology industries. In addition to PTC’s board, Dr. Koppel serves on the board of directors of Trevena, Inc. Dr. Koppel received an M.D. and Ph.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. from Harvard University.
Geoffrey McDonough, M.D. | Swedish Orphan Biovitrum AB (Sobi)
Geoffrey McDonough, M.D. has served as a member of PTC's board of directors since November 2012. Since August 2011, Dr. McDonough has served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a biopharmaceutical company focused on rare diseases. Prior to joining Sobi, Dr. McDonough held several senior leadership positions at Genzyme Corporation from 2002 to June 2011. Prior to joining Genzyme, Dr. McDonough was a practicing internist and pediatrician. Dr. McDonough received a B.A. and a B.Sc. from the University of North Carolina at Chapel Hill and an M.D. from Harvard Medical School.
Stuart W. Peltz, Ph.D. | CEO, PTC Therapeutics, Inc.
Stuart W. Peltz, Ph.D. founded PTC Therapeutics, Inc. in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company's inception. Under his leadership, PTC has grown from a research organization based in the expertise of RNA processes and control to a publically traded company on NASDAQ focused on the discovery, development and commercialization of orally-administered, small-molecule treatments for genetic disorders, oncology and infectious diseases.
Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. He and his team have shown the important interplay between the different RNA biology events that ultimately control protein production in the cell. He was involved in developing the first biochemical and genetic assays investigating the regulation of mRNA turnover subsequently demonstrating the strong connection between the processes of protein production and mRNA turnover. His work was instrumental in identifying and characterizing components of multiple mRNA decay and translation pathways. These findings have been translated to build novel drug discovery platforms and targets that allow PTC to search for potential new drugs to treat genetic disorders, oncology, and infectious diseases. Dr. Peltz’s development of the nonsense readthrough platform led to the discovery of the first approved drug for Duchenne muscular dystrophy in the European Union.
Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He received the 2014 Dr. Sol J. Barer Award for Vision Innovation and Leadership and was recognized as PharmaVoice’s 100 Most Inspiring People in 2009. He is a member of the board of directors for the Biotechnology Industry Organization (BIO) and serves on BIO’s Emerging Companies Section Governing Board. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.
Ronald C. Renaud, Jr. | RaNA Therapeutics
Mr. Renaud currently serves as Chief Executive Officer of RaNA Therapeutics. Previously, he served as the President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., a public biopharmaceutical company, from October 2010 until the company's acquisition by Merck in August 2014. Prior to his role as CEO, Mr. Renaud was the Chief Financial Officer of Idenix from the time he joined Idenix in June 2007 and was additionally appointed chief business officer in June 2010. Prior to joining Idenix, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, from February 2006 to May 2007. He was a senior research analyst and global sector coordinator for JP Morgan Securities from May 2004 until February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud currently serves as a director at Akebia Therapeutics and Chimerix. Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California.
David P. Southwell | Inotek Pharmaceuticals
David P. Southwell has served as a member of PTC's board of directors since December 2005. Mr. Southwell joined Inotek Pharmaceuticals in August 2014 as President and Chief Executive Officer. Mr. Southwell served as the Executive Vice President and Chief Financial Officer of Human Genome Sciences, a biopharmaceutical company, from March 2010 to September 2012, and from 2008 to 2010 served as a member of the company's board of directors. Prior to joining Human Genome Sciences, he served as Executive Vice President and Chief Financial Officer of Sepracor, Inc., a research-based pharmaceutical company, from June 1994 to March 2008. From August 1988 until 1994, Mr. Southwell was associated with Lehman Brothers Inc., a securities firm, in various positions with the investment banking division. Since 2007, Mr. Southwell has served on the board of directors of THL Credit, Inc. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College, where he currently serves on the Board of Overseers.
Glenn D. Steele, Jr., M.D., Ph.D. | Chairman of xG Health Solutions
Glenn D. Steele Jr., MD, PhD serves as Chairman of xG Health Solutions, an independently operated venture Geisinger launched to help healthcare organizations create value and improve quality, leveraging Geisinger intellectual property and expertise on issues such as population-health data analytics, care management and health IT. He is the former President and Chief Executive Officer of Geisinger Health System, an integrated health services organization in central and northeastern Pennsylvania nationally recognized for its innovative use of the electronic health record and the development and implementation of innovative care models. Dr. Steele previously served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, president and chief executive officer of Deaconess Professional Practice Group, Boston, Mass., and chairman of the department of surgery at New England Deaconess Hospital (Boston, Mass.). Dr. Steele is past Chairman of the American Board of Surgery. His investigations have focused on the cell biology of gastrointestinal cancer and pre-cancer and most recently on innovations in healthcare delivery and financing. A prolific writer, he is the author or co-author of more than 488 scientific and professional articles.
Dr. Steele received his bachelor’s degree in history and literature from Harvard College and his medical degree from New York University School of Medicine. He completed his internship and residency in surgery at the University of Colorado, where he was also a fellow of the American Cancer Society. He earned his Ph.D. in microbiology at Lund University in Sweden.
A member of the National Academy of Medicine, Dr. Steele serves as a member on the Roundtable on Value and Science-driven Healthcare, the Committee on the Governance and Financing of Graduate Medical Education, the Vital Directions for Health and Health Care Steering Committee and previously served on the Committee on Reviewing Evidence to Identify Highly Effective Clinical Services (HECS). A fellow of the American College of Surgeons, Dr. Steele is a member of the American Surgical Association, the American Society of Clinical Oncology, and past president of the Society of Surgical Oncology.
Dr. Steele serves on the following boards and national committees: Cepheid Board of Directors, City of Hope Board of Directors, Ingenious Med Board of Directors, PTC Therapeutics Board of Directors, Stratus Video Interpreting Board of Directors, Wellcare Health Plans Inc. Board of Directors, Healthcare Innovation Program (HIP) External Advisory Board (Emory University), the Peterson Center on Healthcare Advisory Board, Institute for Healthcare Optimization Advisory Board, the State Health Care Cost Containment Commission, and Healthcare Executives Network and currently serves as Honorary Chair of the Pennsylvania March of Dimes Prematurity Campaign. Dr. Steele formerly served on the following boards: Agency for Integrated Care (AIC) Singapore, Bucknell University Board of Trustees, Harvard Medical Faculty Physicians Board at Beth Israel Deaconess Medical Center, Premier, Inc. Board (Chairman 2011-2013), Temple University School of Medicine Board of Visitors, Weis Markets, Inc., Congressional Budget Office Panel of Health Advisers, Commonwealth Fund’s Commission on a High Performance Health System, the National Committee for Quality Assurance’s (NCQA) Committee on Performance Measurement, American Hospital Association (AHA) Board of Trustees, also served on the Executive Committee, Systems Governing Council, Long-Range Policy, Committee on Research, and the AHA Physician Leadership Forum Advisory Committee.
Dr. Steele is the recipient of several awards, 2015 AHA's Justin Ford Kimball Innovators Award, 2014 NCHL Gail L. Warden Healthcare Leadership Award, CEO IT Achievement Award (2006); AHA’s Grassroots Champion Award (2007); 8th Annual (2010) AHA Health Research & Education Trust Award and HFMA Board of Directors’ Award (2011). He has been named consecutive times to Modern Healthcare’s 50 Most Powerful Physician Executives in Healthcare, Modern Healthcare’s 100 Most Powerful People in Healthcare and Becker’s Hospital Review 100 Non-Profit Hospital Health System CEOs to-know List.
Dawn Svoronos | Former President of Merck’s Europe/Canada region
Dawn Svoronos has served as a member of PTC’s board of directors since June 2016. She has over 30 years of experience in the pharmaceutical industry, including extensive commercial work at Merck & Co. Inc., where she held roles of increasing seniority for 23 years, prior to her retirement in 2011 as President of Merck’s Europe/Canada region. Previously, Ms. Svoronos served at Merck as President of Canada, Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos is currently chair of the board of directors for Theratechnolgies Inc., a specialty pharmaceutical company that trades on the Toronto Stock Exchange. Ms. Svoronos also serves on the board of Xenon Pharmaceuticals Inc., a Nasdaq-listed biopharmaceutical company and is a member of the board of Agnovos Healthcare Company, a privately held organization in New York. Ms. Svoronos received a BA from Carleton University.
Jerome B. Zeldis, M.D., Ph.D. | Sorrento Therapeutics, Inc.
Jerome B. Zeldis, M.D., Ph.D. has served as a member of our board of directors since September 2012. Dr. Zeldis is currently the Chief Medical Officer and President of Clinical Development at Sorrento Therapeutics, Inc., a clinical-stage public biopharmaceutical company. Until June 2016, Dr. Zeldis served as Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he was employed since 1997. He previously served as Celgene's Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and an M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. Dr. Zeldis also serves on the board of directors of Soligenix, Inc., a public biopharmaceutical company, Alliqua, Inc., a public biomedical company, MetaStat, Inc., a molecular diagnostic company, and BioSig Technologies, Inc., a development stage medical device company.